Wednesday, June 10, 2026

pharma Β· Gastric Adenocarcinoma

Basilea Pharmaceutica

Basilea Pharmaceutica clinical programs β€” 2 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Allschwil, CH HQ
2000 Founded
246 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Allschwil, CH
Founded
2000
Employees
246
Programs
2
Drugs
3
Patents
25
Intelligence Β· Clinical Programs

Basilea Pharmaceutica projects

2 ClinicalTrials.gov programs sponsored by Basilea Pharmaceutica.

Basilea Pharmaceutica has 2 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Derazantinib

    Basilea Pharmaceutica

    Gastric Adenocarcinoma

    phase 2 small molecule terminated

    1 trial
  2. Oral Fosmanogepix

    Basilea Pharmaceutica

    Healthy

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Basilea Pharmaceutica have?

2 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.